| Literature DB >> 24859360 |
Marie Scully1, Mari Thomas2, Mary Underwood2, Henry Watson3, Katherine Langley2, Raymond S Camilleri4, Amanda Clark5, Desmond Creagh6, Rachel Rayment7, Vickie Mcdonald8, Ashok Roy9, Gillian Evans10, Siobhan McGuckin1, Fionnuala Ni Ainle11, Rhona Maclean12, William Lester13, Michael Nash14, Rosemary Scott1, Patrick O Brien1.
Abstract
Pregnancy can precipitate thrombotic thrombocytopenic purpura (TTP). We present a prospective study of TTP cases from the United Kingdom Thrombotic Thrombocytopenic Purpura (UK TTP) Registry with clinical and laboratory data from the largest cohort of pregnancy-associated TTP and describe management through pregnancy, averting fetal loss and maternal complications. Thirty-five women presented with a first TTP episode during pregnancy: 23/47 with their first congenital TTP (cTTP) episode and 12/47 with acute acquired TTP in pregnancy. TTP presented primarily in the third trimester/postpartum, but fetal loss was highest in the second trimester. Fetal loss occurred in 16/38 pregnancies before cTTP was diagnosed, but in none of the 15 subsequent managed pregnancies. Seventeen of 23 congenital cases had a missense mutation, C3178T, within exon 24 (R1060W). There were 8 novel mutations. In acquired TTP presentations, fetal loss occurred in 5/18 pregnancies and 2 terminations because of disease. We also present data on 12 women with a history of nonpregnancy-associated TTP: 18 subsequent pregnancies have been successfully managed, guided by ADAMTS13 levels. cTTP presents more frequently than acquired TTP during pregnancy and must be differentiated by ADAMTS13 analysis. Careful diagnosis, monitoring, and treatment in congenital and acquired TTP have assisted in excellent pregnancy outcomes.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24859360 DOI: 10.1182/blood-2014-02-553131
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113